Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
作者信息
Bernstein Daniel
机构信息
Cardiovascular Institute and Department of Pediatrics, Stanford University, Stanford, CA.
出版信息
Circ Res. 2018 Mar 30;122(7):e64-e65. doi: 10.1161/CIRCRESAHA.118.312921.
Abstract
摘要
相似文献
1
Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
Circ Res. 2018 Mar 30;122(7):e64-e65. doi: 10.1161/CIRCRESAHA.118.312921.
2
Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
Circ Res. 2018 Mar 30;122(7):e62-e63. doi: 10.1161/CIRCRESAHA.118.312918.
3
Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?
Circ Res. 2018 Jan 19;122(2):188-190. doi: 10.1161/CIRCRESAHA.117.312395.
4
[Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Kardiologiia. 2016 Dec;56(12):72-79.
5
Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology.
Toxicol Appl Pharmacol. 2023 Jan 15;459:116362. doi: 10.1016/j.taap.2022.116362. Epub 2022 Dec 30.
6
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Korean J Intern Med. 2016 Jul;31(4):625-33. doi: 10.3904/kjim.2016.017. Epub 2016 Jul 1.
7
Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Eur J Cancer. 2023 May;185:94-104. doi: 10.1016/j.ejca.2023.02.019. Epub 2023 Feb 24.
8
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
JAMA Oncol. 2019 Jun 1;5(6):864-871. doi: 10.1001/jamaoncol.2018.6634.
9
Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.
Cardiovasc Toxicol. 2016 Jan;16(1):5-13. doi: 10.1007/s12012-015-9307-1.
10
Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes.
Curr Opin Cardiol. 2019 May;34(3):289-295. doi: 10.1097/HCO.0000000000000617.
引用本文的文献
1
A photochemical-responsive nanoparticle boosts doxorubicin uptake to suppress breast cancer cell proliferation by apoptosis.
Sci Rep. 2022 Jun 20;12(1):10354. doi: 10.1038/s41598-022-14518-x.
2
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.
Cardiooncology. 2019 Dec 2;5:18. doi: 10.1186/s40959-019-0054-5. eCollection 2019.
本文引用的文献
1
Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?
Circ Res. 2018 Jan 19;122(2):188-190. doi: 10.1161/CIRCRESAHA.117.312395.
2
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
J Clin Oncol. 2016 Mar 10;34(8):854-62. doi: 10.1200/JCO.2015.60.8851. Epub 2015 Dec 23.
3
Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
J Natl Cancer Inst. 2015 Nov 23;108(4). doi: 10.1093/jnci/djv357. Print 2016 Apr.
4
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.
5
Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.
J Clin Oncol. 2015 Aug 20;33(24):2639-45. doi: 10.1200/JCO.2014.59.4473. Epub 2015 May 26.
6
The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Br J Pharmacol. 2015 May;172(9):2246-57. doi: 10.1111/bph.13046. Epub 2015 Feb 27.
7
Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.
Pediatr Blood Cancer. 2015 Apr;62(4):704-9. doi: 10.1002/pbc.25043. Epub 2014 Mar 26.
8
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
Cancer. 2013 Oct 1;119(19):3555-62. doi: 10.1002/cncr.28256. Epub 2013 Jul 16.
9
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25.
10
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
Eur J Cancer. 2011 Jun;47(9):1373-9. doi: 10.1016/j.ejca.2011.03.022. Epub 2011 Apr 20.
Zotero 插件